Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Adductor Canal Block in Fast Track Total Knee Arthroplasty
NCT05962970Completed
- Sponsor
- Mount Sinai Hospital
- Start
- Oct 2023
- Primary completion
- Dec 2025
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Randomised, double-blind trial of ropivacaine in postoperative pain (2 arms), sponsored by Mount Sinai Hospital. Primary endpoint: Opioid consumption in oral morphine equivalent doses at 90 days. Started Oct 2023; status: completed.
02
Drugs
ropivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT05962970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05962970.